(Acquisition of treasury stock pursuant to the provision of its Articles of Incorporation in accordance with Article 165, paragraph 2 of the Companies Act)
Japan, November 5, 2008 – Astellas Pharma Inc. (Headquarters: Tokyo; President and CEO: Masafumi Nogimori, hereinafter called the “the Company”) announced that at the meeting of the Board of Directors held today, a resolution was adopted to acquire its treasury stock pursuant to Article 156 which is applicable in accordance with Article 165, paragraph 3 of the Companies Act.
1.Reasons for the acquisition of treasury stock
To improve capital efficiency and enhance return to shareholders.
2.Contents of acquisition
(1) Class of shares to be acquired: Common stock of the Company
(2) Total number of shares to be acquired:9.0 million shares(maximum)
(The percentage compared to the total number of shares outstanding: 1.88%)
(3) Aggregate amount of acquisition cost: 40 billion yen (maximum)
(4) Period of acquisition: From November 7, 2008 to December 12, 2008
The status of treasury stock as of September 30, 2008:
Total number of shares outstanding: 478,999,755 shares
Number of treasury stock: 24,964,880 shares